Little is known about the interests of the doctors, scientists, and academics on whose advice the UK government relies to manage the pandemic. Attempts to discover more are frequently thwarted, finds Paul D Thacker.
As the number of UK deaths caused by covid-19 reached 50 000 in early November, England enacted a second national lockdown to control the epidemic. Boris Johnson’s government put these measures into action after months of controversial and sometimes confusing policies, including the “rule of six,” regional tiered controls, and directions to “stay alert.” At the same time, the government has faced mounting questions about procurement decisions, from personal protective equipment to testing kits, from vaccine deals to the services of logistics companies.
Calls for greater transparency around such decisions have included those bodies focused on science and health, such as the Scientific Advisory Group for Emergencies (SAGE), as well as taskforces charged with advising on vaccines and testing. Although Downing Street has become more transparent in disclosing the advice of SAGE, it has kept members’ financial conflicts of interest unpublished and shown little concern that advisers to the coronavirus Vaccine Taskforce have financial interests in pharmaceutical companies receiving government contracts. When The BMJ sought further information on these bodies, such as lists of members’ interests, the information was denied or requests were unanswered.